SPARC gets orphan drug designation from USFDA for novel kinase inhibitor

The Orphan Drug Act provides economic incentives to encourage the development of drugs for diseases affecting fewer than 2 lakh people in the US, Sun Pharma Advanced Research Company (SPARC) said in a filing to BSE.

Original source: https://health.economictimes.indiatimes.com/news/pharma/sparc-gets-orphan-drug-designation-from-usfda-for-novel-kinase-inhibitor/70126780?utm_source=RSS&utm_medium=ETRSS

Related Posts